摘要
背景:糖结合蛋白广泛分布于人类体内,在生物过程中起着至关重要的作用.他们在炎症和免疫反应中的参与使其变得越来越像甘氨酸结合蛋白可能是有价值的治疗靶点。目的:本综述旨在提供抗体临床进展的最新资料。作为潜在靶点的糖结合蛋白。 结果与结论:目前已开发出多种针对不同疾病的治疗性抗体,包括CD22、CD33、DEC-205和CD62P。临床投资免疫测定显示了一种抗CD 22抗体药物结合治疗的益处,并得到了监管机构的批准。这些抗体的临床研究进展为治疗多种疾病(包括炎症、自身免疫性疾病和血液恶性肿瘤)提供了良好的治疗靶点。
关键词: 甘氨酸结合蛋白,凝集素,抗体,临床发育,炎症,自身免疫性疾病,血液学 malignance恶意,有害
Current Drug Targets
Title:Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins
Volume: 19 Issue: 13
关键词: 甘氨酸结合蛋白,凝集素,抗体,临床发育,炎症,自身免疫性疾病,血液学 malignance恶意,有害
摘要: Background: Glycan-binding proteins are widely distributed in human and play an essential role in biological processes. Their involvements in inflammatory and immune responses make it increasingly likely that the glycan-binding proteins may represent valuable therapeutic targets.
Objective: The current review aims to provide information on recent advancements in clinical developments of antibodies against glycan-binding proteins as potential targets.
Results and Conclusion: There are several therapeutic antibodies being developed targeting glycanbinding proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies have provided great promises in therapeutic targeting of more glycan-binding proteins for treating multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies.
Export Options
About this article
Cite this article as:
Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins, Current Drug Targets 2018; 19 (13) . https://dx.doi.org/10.2174/1389450119666180308144313
DOI https://dx.doi.org/10.2174/1389450119666180308144313 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Leukemia Microenvironment
Current Drug Targets Alternative Splice Variants of Survivin as Potential Targets in Cancer
Current Drug Discovery Technologies Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry Recent Progress of Src Family Kinase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Targeted Taxane Delivery Systems: Recent Advances
Drug Delivery Letters Schizophrenia: A Systematic Review of the Disease State, Current Therapeutics and their Molecular Mechanisms of Action
Current Medicinal Chemistry IgE, Allergic Diseases, and Omalizumab
Current Pharmaceutical Design Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
Current Pharmaceutical Design Targeting the NF-κB pathway in prostate cancer: a promising therapeutic approach?
Current Drug Targets Advances of Mesenchymal Stem Cells Derived from Bone Marrow and Dental Tissue in Craniofacial Tissue Engineering
Current Stem Cell Research & Therapy Adjudin - A Male Contraceptive with Other Biological Activities
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Stem Cell Based Therapy for Skeletal Muscle Diseases
Current Stem Cell Research & Therapy Delivery of Nanoparticles for Treatment of Brain Tumor
Current Drug Metabolism State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Recent Patents on Anti-Cancer Drug Discovery Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation
Current Gene Therapy Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation
Current Medicinal Chemistry Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Current Drug Delivery